Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

Transfusion

Volumn 54, Issue 6, 2014, Pages 1542-1551

  Cheong, June Won ^a   Kim, Hyeoung Joon ^b   Lee, Kyoo Hyung ^c   Yoon, Sung Soo ^d   Lee, Jae Hoon ^e   Park, Hee Sook ^f   Kim, Ho Young ^g   Shim, Hyeok ^h   Seong, Chu Myung ⁱ   Kim, Chul Soo ^j   Chung, Jooseop ^k   Hyun, Myung Soo ^l   Jo, Deog Yeon ^m   Jung, Chul Won ⁿ   Sohn, Sang Kyun ^o   Yoon, Hwi Joong ^p   Kim, Byung Soo ^q   Joo, Young Don ^r   Park, Chi Young ^s   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chonnam National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Gachon University College of Medicine   (South Korea)

^f Soonchunhyang University   (South Korea)

^g Hallym University   (South Korea)

^h Wonkwang University   (South Korea)

ⁱ Ewha Womans University School of Medicine   (South Korea)

^j Inha University   (South Korea)

^k Pusan National University   (South Korea)

^l Yeungnam University   (South Korea)

^m Chungnam National University   (South Korea)

ⁿ Sungkyunkwan University   (South Korea)

^o Kyungpook National University   (South Korea)

^p Kyung Hee University   (South Korea)

^q Korea University   (South Korea)

^r Inje University   (South Korea)

^s Chosun University   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERASIROX; FERRITIN; HEMOGLOBIN; IRON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APLASTIC ANEMIA; ARTICLE; DRUG EFFICACY; DRY WEIGHT; FEMALE; FERRITIN BLOOD LEVEL; HEMATOLOGIC FUNCTION; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; LIVER FUNCTION; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANEMIA, APLASTIC; BENZOATES; BLOOD TRANSFUSION; FEMALE; FERRITINS; HUMANS; IRON; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 84902280549     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12507     Document Type: Article

References (35)

1. Shander A, Sazama K,. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 2010; 50: 1144-1155.
2. Andrews NC,. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986-1995.
3. Olivieri NF,. Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38 (1 Suppl 1): 57-62.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, etal. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850: 227-231.
5. Shalitin S, Carmi D, Weintrob N, etal. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005; 74: 93-100.
6. Kwiatkowski JL, Kim HY, Thompson AA, etal.; Thalassemia Clinical Research Network. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012; 119: 2746-2753.
7. Garcia-Manero G,. Myelodysplastic syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 490-498.
8. Lee JW, Yoon SS, Shen ZX, etal.; EPIC Study Investigators. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2012; 116: 2448-2454.
9. Brittenham GM, Griffith PM, Nienhuis AW, etal. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.
10. Cermak J, Jonasova A, Vondrakova J, etal. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011; 35: 217-227.
11. Cappellini MD, Bejaoui M, Agaoglu L, etal. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118: 884-893.
12. Raptis A, Duh MS, Wang ST, etal. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2010; 50: 190-199.
13. Gattermann N,. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008; 88: 24-29.
14. St Pierre TG, Clark PR, Chua-anusorn W, etal. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861.
15. Hussain MA, Green N, Flynn DM, etal. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976; 2: 1278-1280.
16. Olivieri NF, Brittenham GM, McLaren CE, etal. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339: 417-423.
17. Galanello R, Campus S,. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009; 122: 155-164.
18. Piga A, Roggero S, Salussolia I, etal. Deferiprone. Ann N Y Acad Sci 2010; 1202: 75-78.
19. Nick H, Wong A, Acklin P, etal. ICL670A: preclinical profile. Adv Exp Med Biol 2002; 509: 185-203.
20. Nisbet-Brown E, Olivieri NF, Giardina PJ, etal. Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
21. Piga A, Galanello R, Forni GL, etal. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880.
22. Galanello R, Piga A, Forni GL, etal. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91: 1343-1351.
23. Cappellini MD, Cohen A, Piga A, etal. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
24. Metzgeroth G, Dinter D, Schultheis B, etal. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann Hematol 2008; 88: 301-310.
25. Porter J, Galanello R, Saglio G, etal. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-176.
26. List AF, Baer MR, Steensma DP, etal. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012; 30: 2134-2139.
27. Nolte F, Höchsmann B, Giagounidis A, etal. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 2013; 92: 191-198.
28. Malcovati L, Porta MG, Pascutto C, etal. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
29. Lee JW, Kim CC,. The activity of hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2008; 42: S92-95.
30. Watt RK,. The many faces of the octahedral ferritin protein. Biometals 2011; 24: 489-500.
31. Taher AT, Musallam KM, Inati A,. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009; 33: S46-57.
32. Lee JW, Yoon SS, Shen ZX, etal. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post-hoc analysis from the EPIC study. Haematologica 2013; 98: 1045-1048.
33. Lee SE, Yahng SA, Cho BS, etal. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematol 2013; 129: 72-77.
34. Gattermann N, Finelli C, Della Porta M, etal. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012; 97: 1364-1371.
35. Britton RS, Leicester KL, Bacon BR,. Iron toxicity and chelation therapy. Int J Hematol 2002; 76: 219-228.